Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F FROMM

Showing results (211-220 of 233) with videos related to

Pageof 24
Sort By:
Clinical Pharmacology and Therapeutics|May 9, 2006
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humansLaurent Becquemont, Hartmut Glaeser, Siegfried Drescher, et al.
Clinical Pharmacology and Therapeutics|November 12, 2002
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 geneAndreas Johne, Karla Köpke, Thomas Gerloff, et al.
Clinical Pharmacology and Therapeutics|January 15, 2014
Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjectsS Misaka, J Yatabe, F Müller, et al.
Clinical Pharmacokinetics|August 24, 2007
Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated effluxSvitlana Igel, Siegfried Drescher, Thomas Mürdter, et al.
The Journal of Biological Chemistry|April 10, 2002
Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestineOliver Burk, Heike Tegude, Ina Koch, et al.
Clinical Pharmacology and Therapeutics|March 22, 2002
Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transportersHartmut Glaeser, Siegfried Drescher, Heiko van der Kuip, et al.
JCO Oncology Practice|June 7, 2024
A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation CenterLisa Cuba, Pauline Dürr, Katja Gessner, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 27, 2018
Drugs linked to plasma homoarginine in chronic kidney disease patients-a cross-sectional analysis of the German Chronic Kidney Disease cohortRenke Maas, Maren Mieth, Stephanie I Titze, et al.
Clinical Pharmacology and Therapeutics|December 22, 2025
Extent and Incidence of Pseudo-Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real-World DataMichael I Sponfeldner, Pauline Dürr, Phyllis Lensker, et al.
Pharmaceutical Research|April 23, 1999
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoproteinR B Kim, C Wandel, B Leake, et al.
Pageof 24

Showing results (211-220 of 233) with videos related to

Sort By:
Pageof 24
Clinical Pharmacology and Therapeutics|May 9, 2006
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humansLaurent Becquemont, Hartmut Glaeser, Siegfried Drescher, et al.
Clinical Pharmacology and Therapeutics|November 12, 2002
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 geneAndreas Johne, Karla Köpke, Thomas Gerloff, et al.
Clinical Pharmacology and Therapeutics|January 15, 2014
Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjectsS Misaka, J Yatabe, F Müller, et al.
Clinical Pharmacokinetics|August 24, 2007
Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated effluxSvitlana Igel, Siegfried Drescher, Thomas Mürdter, et al.
The Journal of Biological Chemistry|April 10, 2002
Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestineOliver Burk, Heike Tegude, Ina Koch, et al.
Clinical Pharmacology and Therapeutics|March 22, 2002
Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transportersHartmut Glaeser, Siegfried Drescher, Heiko van der Kuip, et al.
JCO Oncology Practice|June 7, 2024
A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation CenterLisa Cuba, Pauline Dürr, Katja Gessner, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 27, 2018
Drugs linked to plasma homoarginine in chronic kidney disease patients-a cross-sectional analysis of the German Chronic Kidney Disease cohortRenke Maas, Maren Mieth, Stephanie I Titze, et al.
Clinical Pharmacology and Therapeutics|December 22, 2025
Extent and Incidence of Pseudo-Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real-World DataMichael I Sponfeldner, Pauline Dürr, Phyllis Lensker, et al.
Pharmaceutical Research|April 23, 1999
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoproteinR B Kim, C Wandel, B Leake, et al.
Pageof 24